Ovarian cancer is the seventh most common cancer in women worldwide, with 239 000 new
cases diagnosed in 2012. 1 As with many other types of cancer, geographical variation in …

Introduction Surgical management of gynecologic cancer can cause short-and long-term
effects on sexuality, reproductive function, and overall quality of life (QOL)(eg, sexual …

Background The cost-effectiveness of population-based panel testing for high-and moderate-
penetrance ovarian cancer (OC)/breast cancer (BC) gene mutations is unknown. We …

Background: Population-based testing for BRCA1/2 mutations detects the high proportion of
carriers not identified by cancer family history (FH)–based testing. We compared the cost …

Importance Moving to multigene testing for all women with breast cancer (BC) could identify
many more mutation carriers who can benefit from precision prevention. However, the cost …

Clinical criteria/Family history-based BRCA testing misses a large proportion of BRCA
carriers who can benefit from screening/prevention. We estimate the cost-effectiveness of …

Importance Pathogenic variants (PVs) inBRCA1, BRCA2, PALB2, RAD51C, RAD51D, and
BRIP1cancer susceptibility genes (CSGs) confer an increased ovarian cancer (OC) risk …

Background Our study aimed to establish 'real-world'performance and cost-effectiveness of
ovarian cancer (OC) surveillance in women with pathogenic germline BRCA1/2 variants …

Background Population-based BRCA1/BRCA2 testing has been found to be cost-effective
compared with family history–based testing in Ashkenazi-Jewish women were> 30 years old …

Background Women with pathogenic BRCA1 and BRCA2 mutations possess a high risk of
developing breast and ovarian cancer. They face difficult choices when considering …